Intel doles out $117M to disruptive startups, including 2 in healthcare

Fourteen startups are getting a share of $117 million from Intel Capital, which is encouraging the recipients to spend the money on efforts to “disrupt their industries.” For two of the companies, the industry is healthcare and the disruptive innovation involves AI.

Medical Informatics of Houston, creator of the Sickbay monitoring and analytics platform, is working to incorporate AI in its anywhere/anytime remote monitoring capabilities. The aim is to “deploy real-time, predictive, critical care analytics that get ahead of deterioration and risk and enable data-driven medicine and patient-centered care,” according to an announcement.

Meanwhile Reveal Biosciences of San Diego will likely use the dollars to further develop its ImageDx, a proprietary deep-learning platform that “delivers pathologists and scientists a novel class of actionable, quantitative data to accelerate research and enhance patient care.”

Intel Capital president Wendell Brooks said the 14 companies “are shifting the way we think about artificial intelligence, communications, manufacturing and healthcare—areas that will become increasingly essential in coming years as the linchpins of a smarter, more connected society.”

The announcement came April 1 during an Intel summit in Phoenix.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.